KalVista Pharmaceuticals (NASDAQ:KALV) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.
Separately, BTIG Research lifted their price target on shares of KalVista Pharmaceuticals from $18.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, October 16th.
KalVista Pharmaceuticals (NASDAQ:KALV) traded up $0.04 during trading on Friday, hitting $10.76. 23,890 shares of the stock traded hands, compared to its average volume of 51,916. KalVista Pharmaceuticals has a 1 year low of $5.48 and a 1 year high of $15.80.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/04/kalvista-pharmaceuticals-kalv-stock-rating-upgraded-by-valuengine.html.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.